Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis A Randomized Phase IIa Trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10295596" target="_blank" >RIV/00216208:11110/15:10295596 - isvavai.cz</a>
Alternative codes found
RIV/00023728:_____/15:#0005020
Result on the web
<a href="http://dx.doi.org/10.1002/art.39083" target="_blank" >http://dx.doi.org/10.1002/art.39083</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/art.39083" target="_blank" >10.1002/art.39083</a>

Result language
angličtina
Original language name
Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis A Randomized Phase IIa Trial
Original language description
Objective. Interleukin-20 (IL-20) is implicated in the pathogenesis of rheumatoid arthritis (RA). The efficacy, safety, and tolerability of NNC0109-0012, a selective anti-IL-20 recombinant human monoclonal antibody (mAb), were assessed in patients with active RA who had an inadequate response to methotrexate therapy. Methods. Sixty-seven patients with RA were enrolled and randomized (2:1) to receive NNC0109-0012 (3 mg/kg per week, subcutaneously) or placebo in a phase IIa, double-blind, 12-week trial with a 13-week followup. The primary end point was change in the Disease Activity Score in 28 joints based on C-reactive protein level (DAS28-CRP) from baseline to week 12. Results. In patients treated with NNC0109-0012, the primary end point, improvementin the DAS28-CRP at week 12, was achieved (estimated difference -0.88; P=0.02), with significant improvement starting at week 1. A greater response was observed in seropositive patients (estimated difference -1.66; P<0.001), which was sus
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FP - Other medical fields
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)